NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed two agreements with cancer startup Agios Pharmaceuticals related to its X-Man cell-line technology.
The Cambridge, UK-based firm said that it has licensed certain X-Man cell lines, including major cancer-causing genes and their matched normal genetic backgrounds. In addition, it said that it would screen a number of Agios lead compounds on a wide panel of genotypes.
Horizon said that its technology should enable Agios to understand how key oncogenic pathways of cancer cells survive in tumors and to predict the genomic makeup of tumors in the responsive patient types.
Cambridge, Mass.-based Agios will pay Horizon undisclosed up-front and renewal fees during the term of the agreements. They expect to begin the collaboration this month.